News & Publications SPECTRE Newsletter-HHS Region VI-June 19, 2023 June 19, 2023, 00:00 AM by Maegan Traveler Sam Houston State University Roundtable Meeting June 16, 2023, 12:02 PM by Maegan Traveler SPECTRE Program Managers Kara Marshall and Corri Levine attend a roundtable meeting hosted by Sam Houston State University (SHSU), Institute of Homeland Security. John Suarez of SHSU, Mike Mastrangelo of UTMB, and UTMB Assistant Chief of Police David DeOre are seen accompanying them. Newest Episode of The Infectious Science Podcast: Exploring One Health in Nigeria: Cross Training, Arboviruses, and Lassa Fever with Top Scientists June 12, 2023, 11:44 AM by Maegan Traveler In this fascinating episode, we dive into the West African Center for Emerging Infection Diseases program, and its goal to rebuild expertise on arboviruses, collect and identify mosquitoes, and assay them for potential virus-carrying. Dr. McLellan speaks on Houston Town Square June 12, 2023, 09:04 AM by Maegan Traveler Talk of the Town: President Trump’s Legal Troubles, the 2024 Presidential Race, The Tony Awards, Summer Entertainment, and More SPECTRE Newsletter-HHS Region VI-June 12,2023 June 12, 2023, 00:00 AM by Maegan Traveler Paper Patients Webinar June 7, 2023, 08:38 AM by Maegan Traveler SPECTRE is offering this webinar as a means to discuss practical considerations for health care institutions and partners when presented with a patient suspected of having a special pathogen. We will use example "paper patients "to walk through the steps necessary to provide appropriate care while maintaining public health and healthcare worker safety. SPECTRE Newsletter-HHS Region VI- June 5, 2023 June 5, 2023, 00:00 AM by Maegan Traveler Journal Article: Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case May 31, 2023, 13:50 PM by Maegan Traveler New article published in Open Forum of Infectious Diseases co-authored by SPECTRE’s Dr. Corri Levine: Appropriate representation is vital when conducting clinical trials and this is just as important during emerging infectious disease outbreaks. The Adaptive COVID-19 Treatment Trial (ACTT) was one of the first trials to test therapeutics against COVID-19, initiated early in the pandemic when very little was known about the disease and susceptible populations. This paper used ACTT as a model for selecting appropriate comparators when evaluating trial representation. SPECTRE Newsletter-HHS Region VI-May 29, 2023 May 29, 2023, 00:00 AM by Maegan Traveler SPECTRE Newsletter-HHS-Region VI- May 22, 2023 May 22, 2023, 00:00 AM by Maegan Traveler SPECTRE Newsletter-HHS Region VI- May 15, 2023 May 15, 2023, 00:00 AM by Maegan Traveler SPECTRE Newsletter-HHS Region VI-May 8,2023 May 8, 2023, 00:00 AM by Maegan Traveler Infection Prevention 102: Preparedness May 4, 2023, 09:46 AM by Kiki Baldwin Registration is now open! This course will briefly discuss infection prevention and control practices in how to conduct a risk assessment, and how to implement effective resource and waste management practices. Attendees will hear lessons learned in the field from the Director of the UTMB SPECTRE Program: Dr. Susan McLellan, MD, MPH GOARN Partners Meeting for the Americas May 4, 2023, 08:29 AM by Kiki Baldwin Dr. McLellan on the panel at the Global Outbreak Alert and Response Network (GOARN) Partners Meeting for the Americas in Panama City, Panama, May 2nd-4th. Session: One Health and surveillance for EIDs SPECTRE Newsletter-HHS Region VI-May 1, 2023 May 1, 2023, 00:00 AM by Maegan Traveler Special Pathogen Preparedness-SPPH Symposium Student Poster April 25, 2023, 08:39 AM by Kara Marshall SPECTRE Newsletter-HHS Region VI - April 24, 2023 April 24, 2023, 00:00 AM by Kara Marshall Journal Article: Baricitinib treatment of COVID-19 is associated with a reduction of secondary infections April 20, 2023, 14:43 PM by Kiki Baldwin New article published in Open Forum of Infectious Diseases co-authored by SPECTRE’s Dr. Corri Levine: “Baricitinib treatment of COVID-19 is associated with a reduction of secondary infections.” A secondary analysis of patients enrolled in the ACTT-2 randomized controlled trial found that COVID-19 patients treated with remdesivir plus baricitinib were less likely to have a secondary infection during their care compared to those treated with remdesivir alone. This is a novel benefit for use of baricitinib and supports the safety of this therapeutic for use in COVID-19 patients. NETEC Situation Report: Things to Know About Avian Influeza A (H3N8) April 17, 2023, 09:31 AM by Kiki Baldwin On the #NETEC Situation Report for April 14, 2023, Dr. Corri Levine, a NETEC expert and virologist at The University of Texas Medical Branch shares three things you should know about avian influenza. SPECTRE Newsletter-HHS Region VI - April 17, 2023 April 17, 2023, 00:00 AM by Kara Marshall 1 2 3 4 5 6 7 8
Sam Houston State University Roundtable Meeting June 16, 2023, 12:02 PM by Maegan Traveler SPECTRE Program Managers Kara Marshall and Corri Levine attend a roundtable meeting hosted by Sam Houston State University (SHSU), Institute of Homeland Security. John Suarez of SHSU, Mike Mastrangelo of UTMB, and UTMB Assistant Chief of Police David DeOre are seen accompanying them.
Newest Episode of The Infectious Science Podcast: Exploring One Health in Nigeria: Cross Training, Arboviruses, and Lassa Fever with Top Scientists June 12, 2023, 11:44 AM by Maegan Traveler In this fascinating episode, we dive into the West African Center for Emerging Infection Diseases program, and its goal to rebuild expertise on arboviruses, collect and identify mosquitoes, and assay them for potential virus-carrying.
Dr. McLellan speaks on Houston Town Square June 12, 2023, 09:04 AM by Maegan Traveler Talk of the Town: President Trump’s Legal Troubles, the 2024 Presidential Race, The Tony Awards, Summer Entertainment, and More
Paper Patients Webinar June 7, 2023, 08:38 AM by Maegan Traveler SPECTRE is offering this webinar as a means to discuss practical considerations for health care institutions and partners when presented with a patient suspected of having a special pathogen. We will use example "paper patients "to walk through the steps necessary to provide appropriate care while maintaining public health and healthcare worker safety.
Journal Article: Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case May 31, 2023, 13:50 PM by Maegan Traveler New article published in Open Forum of Infectious Diseases co-authored by SPECTRE’s Dr. Corri Levine: Appropriate representation is vital when conducting clinical trials and this is just as important during emerging infectious disease outbreaks. The Adaptive COVID-19 Treatment Trial (ACTT) was one of the first trials to test therapeutics against COVID-19, initiated early in the pandemic when very little was known about the disease and susceptible populations. This paper used ACTT as a model for selecting appropriate comparators when evaluating trial representation.
Infection Prevention 102: Preparedness May 4, 2023, 09:46 AM by Kiki Baldwin Registration is now open! This course will briefly discuss infection prevention and control practices in how to conduct a risk assessment, and how to implement effective resource and waste management practices. Attendees will hear lessons learned in the field from the Director of the UTMB SPECTRE Program: Dr. Susan McLellan, MD, MPH
GOARN Partners Meeting for the Americas May 4, 2023, 08:29 AM by Kiki Baldwin Dr. McLellan on the panel at the Global Outbreak Alert and Response Network (GOARN) Partners Meeting for the Americas in Panama City, Panama, May 2nd-4th. Session: One Health and surveillance for EIDs
Special Pathogen Preparedness-SPPH Symposium Student Poster April 25, 2023, 08:39 AM by Kara Marshall
Journal Article: Baricitinib treatment of COVID-19 is associated with a reduction of secondary infections April 20, 2023, 14:43 PM by Kiki Baldwin New article published in Open Forum of Infectious Diseases co-authored by SPECTRE’s Dr. Corri Levine: “Baricitinib treatment of COVID-19 is associated with a reduction of secondary infections.” A secondary analysis of patients enrolled in the ACTT-2 randomized controlled trial found that COVID-19 patients treated with remdesivir plus baricitinib were less likely to have a secondary infection during their care compared to those treated with remdesivir alone. This is a novel benefit for use of baricitinib and supports the safety of this therapeutic for use in COVID-19 patients.
NETEC Situation Report: Things to Know About Avian Influeza A (H3N8) April 17, 2023, 09:31 AM by Kiki Baldwin On the #NETEC Situation Report for April 14, 2023, Dr. Corri Levine, a NETEC expert and virologist at The University of Texas Medical Branch shares three things you should know about avian influenza.